DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Price Performance

Shares of DRRX stock opened at $0.77 on Monday. The stock has a market cap of $23.93 million, a P/E ratio of -1.26 and a beta of 0.91. The company has a fifty day moving average price of $0.81 and a two-hundred day moving average price of $1.08. DURECT has a one year low of $0.70 and a one year high of $1.88.

Institutional Trading of DURECT

A number of hedge funds have recently modified their holdings of the stock. Jane Street Group LLC lifted its stake in shares of DURECT by 266.0% during the 4th quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 28,486 shares during the last quarter. Richmond Brothers Inc. lifted its stake in shares of DURECT by 12.2% during the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock worth $961,000 after buying an additional 138,920 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares during the last quarter. Institutional investors and hedge funds own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.